4.43k followers • 31 symbols Watchlist by Yahoo Finance
Follow this list to discover and track large drug and biotechnology companies.
Curated by Yahoo Finance
Follow this list to discover and track large drug and biotechnology companies. These companies develop specialty drugs and treatments for various diseases and medical conditions. Although there are risks associated with the success of the drug, those that succeed tend to have a strong series of earnings growth over a period of time, especially when they are backed by patents.
The list includes stocks priced at $5 or more with a three month average daily trading volume in excess of 200,000 shares. This list is generated daily and sorted by market cap; the gains are based on the latest closing price and limited to the top 30 stocks that meet the criteria.
This watchlist is similar to a discontinued watchlist called Battling Cancer.
Yahoo Finance employs sophisticated algorithms to monitor and detect trends in the Global Financial Markets. We bring these insights to you in the form of watchlists.
Find other winning investment ideas with the Yahoo Finance Screener.How are these weighted?
The stocks in this watchlist are weighted equally.
|Watchlist||Change today||1-month return||1-year return||Total return|
|Biotech and Drug Stocks||+1.13%||-||-||-|
|Symbol||Company name||Last price||Change||% change||Market time||Volume||Avg vol (3-month)||Market cap|
|JNJ||Johnson & Johnson||171.79||+1.81||+1.06%||4:00 pm GMT-4||5.02M||6.69M||452.39B|
|RHHBY||Roche Holding AG||47.03||+0.61||+1.31%||3:59 pm GMT-4||885.93k||1.29M||329.23B|
|LLY||Eli Lilly and Company||244.15||+5.66||+2.37%||4:02 pm GMT-4||2.45M||3.43M||234.15B|
|PFE||Pfizer Inc.||41.68||+0.21||+0.51%||4:02 pm GMT-4||17.94M||25.01M||233.31B|
|NVO||Novo Nordisk A/S||90.75||+2.53||+2.87%||4:00 pm GMT-4||1.65M||908.67k||209.57B|
|ABBV||AbbVie Inc.||118.19||+0.65||+0.55%||4:02 pm GMT-4||4.34M||6.37M||208.75B|
|NVS||Novartis AG||91.57||+0.49||+0.54%||4:00 pm GMT-4||1.64M||1.81M||205.78B|
|MRK||Merck & Co., Inc.||77.54||+1.01||+1.32%||4:02 pm GMT-4||6.56M||12.12M||196.34B|
|AZN||AstraZeneca PLC||58.23||+0.27||+0.47%||4:00 pm GMT-4||14.13M||10.43M||180.92B|
|BMY||Bristol-Myers Squibb Company||68.34||+0.38||+0.56%||4:00 pm GMT-4||7.09M||9.64M||152.59B|
|AMGN||Amgen Inc.||247.72||+2.98||+1.22%||4:00 pm GMT-4||1.59M||2.61M||142.33B|
|MRNA||Moderna, Inc.||348.83||+25.35||+7.84%||4:00 pm GMT-4||23.39M||12.55M||140.07B|
|SNY||Sanofi||51.86||+0.44||+0.86%||4:00 pm GMT-4||2.02M||1.36M||129.91B|
|GSK||GlaxoSmithKline plc||39.51||+0.28||+0.71%||4:00 pm GMT-4||3.76M||4.25M||99.40B|
|ZTS||Zoetis Inc.||203.59||+3.05||+1.52%||4:03 pm GMT-4||932.25k||1.78M||96.66B|
|GILD||Gilead Sciences, Inc.||69.02||+0.37||+0.54%||4:00 pm GMT-4||3.40M||6.84M||86.56B|
|BNTX||BioNTech SE||281.96||+0.98||+0.35%||4:00 pm GMT-4||4.46M||3.12M||68.10B|
|REGN||Regeneron Pharmaceuticals, Inc.||586.35||-0.53||-0.09%||4:00 pm GMT-4||628.25k||758.83k||62.47B|
|BAYRY||Bayer Aktiengesellschaft||14.97||-0.03||-0.20%||3:59 pm GMT-4||578.23k||385.49k||59.22B|
|TAK||Takeda Pharmaceutical Company Limited||16.86||+0.05||+0.30%||4:00 pm GMT-4||914.04k||2.02M||53.16B|
|VRTX||Vertex Pharmaceuticals Incorporated||200.5||+4.48||+2.29%||4:00 pm GMT-4||2.89M||2.20M||51.90B|
|BIIB||Biogen Inc.||325.4||-0.96||-0.29%||4:00 pm GMT-4||1.02M||2.01M||48.99B|
|ALXN||Alexion Pharmaceuticals, Inc.||182.5||-||-||4:00 pm GMT-4||3.00||4.06M||40.34B|
|GMAB||Genmab A/S||44.85||+0.49||+1.10%||4:00 pm GMT-4||218.87k||501.58k||29.38B|
|SGEN||Seagen Inc.||145.6||+2.27||+1.58%||4:00 pm GMT-4||803.34k||805.72k||26.42B|
|RPRX||Royalty Pharma plc||40.33||-0.03||-0.07%||4:00 pm GMT-4||1.00M||1.94M||24.49B|
|HZNP||Horizon Therapeutics Public Limited Company||101.05||+0.98||+0.98%||4:00 pm GMT-4||1.61M||1.55M||22.71B|
|ALNY||Alnylam Pharmaceuticals, Inc.||182.41||+0.60||+0.33%||4:00 pm GMT-4||512.28k||635.49k||21.44B|
|CTLT||Catalent, Inc.||116.26||+1.07||+0.93%||4:02 pm GMT-4||558.51k||912.30k||19.80B|
|TECH||Bio-Techne Corporation||474.4||+5.22||+1.11%||4:00 pm GMT-4||116.92k||252.81k||18.45B|
Novo Nordisk (NYSE: NVO) recently announced that it's buying Prothena's (NASDAQ: PRTA) transthetyrin amyloidosis (ATTR) cardiomyopathy program for up to $1.2 billion. In this Motley Fool Live video recorded on July 14, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss why Novo, which is best known for its diabetes franchise, is buying a rare-disease drug candidate. There is a company, I don't know that we've talked about much, if at all in the past, Brian, Novo Nordisk.
Over the past year, these small-cap drugmakers have done well by their shareholders, and more big catalysts could be coming.
Here are three value stocks to buy for the second half of 2021. With such a low valuation relative to its peers, you might think that AbbVie would be struggling. The company's revenue grew 51% year over year in the first quarter of 2021.